Promethera Biosciences (Belgium) a clinical stage biotechnology company focused on adult stem cell treatments for liver diseases, closed a $31.4 Series B financing. Participants include Vesalius Biocapital, SRIW, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Sopartec, Boehringer Ingelheim Ventures, Shire Ventures, Mitsui Global Investment, ATMI and Sambrinvest.

Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.